Treatment response in CML patients with e1a2 BCR-ABL fusion transcripts
| Age/ sex . | CML f/u, mo . | Monocyte, ×109/L (% of WBC) . | Frontline . | 1st salvage . | 2nd salvage . | 3rd salvage . | Current status . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rx . | CMLstage . | Bestresponse . | Rx, mo/D . | Rx . | CMLstage . | Bestresponse . | Rx,mo/D . | Rx . | CMLstage . | Bestresponse . | Rx,mo/D . | Rx . | CMLstage . | Bestresponse . | Rx,mo/D . | ||||
| 64/M | 36 | 12 (13) | IM 400 | CP | CHR | 6/hem relapse | IM 800 | CP | CHR | 9/subopt response | Dasat.* 140 → 100 → 50 → 40 | CP | PCyR | 18/subopt response | Nilot† 800 → 400 | CP | CHR | 3+/n.a. | Alive |
| 63/M | 114 | 1.2 (23)‡ | IFN | AP | NR | 2/intolerant | IM 600 → 800 | AP | CCyR§ | 108+/ n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | Alive |
| 78/M | 24 | 21 (17)‖ | IM 400 → 200¶ → 400 | CP | CHR | 23/hem relapse | Dasat. 100 | CP | CHR | 1+/n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | Alive |
| Age/ sex . | CML f/u, mo . | Monocyte, ×109/L (% of WBC) . | Frontline . | 1st salvage . | 2nd salvage . | 3rd salvage . | Current status . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rx . | CMLstage . | Bestresponse . | Rx, mo/D . | Rx . | CMLstage . | Bestresponse . | Rx,mo/D . | Rx . | CMLstage . | Bestresponse . | Rx,mo/D . | Rx . | CMLstage . | Bestresponse . | Rx,mo/D . | ||||
| 64/M | 36 | 12 (13) | IM 400 | CP | CHR | 6/hem relapse | IM 800 | CP | CHR | 9/subopt response | Dasat.* 140 → 100 → 50 → 40 | CP | PCyR | 18/subopt response | Nilot† 800 → 400 | CP | CHR | 3+/n.a. | Alive |
| 63/M | 114 | 1.2 (23)‡ | IFN | AP | NR | 2/intolerant | IM 600 → 800 | AP | CCyR§ | 108+/ n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | Alive |
| 78/M | 24 | 21 (17)‖ | IM 400 → 200¶ → 400 | CP | CHR | 23/hem relapse | Dasat. 100 | CP | CHR | 1+/n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | Alive |
CML indicates chronic myeloid leukemia; f/u, follow-up; D, reason for drug discontinuation; WBC, white blood cell count; Gran, granulocytes; M, male; Rx, treatment; IM, imatinib mesylate; IFN, interferon α; Dasat, dasatinib; Nilot, nilotinib; CP, chronic phase; AP, accelerated phase; CHR, complete hematologic response; NR, no response; CCyR, complete cytogenetic response; PCyR, partial cytogenetic response; hem, hematologic; subopt, suboptimal; and n.a., not applicable.
Dose reduced due to recurrent pleural effusions.
Dose reduced due to skin rash.
Obtained while on treatment with imatinib.
Bone marrow with persistent panhyperplasia, dysgranulopoiesis, and monocytosis.
Absolute lymphocytosis from associated chronic lymphocytic leukemia.
Dose reduced due to myelosuppression.